Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8018093rdf:typepubmed:Citationlld:pubmed
pubmed-article:8018093lifeskim:mentionsumls-concept:C1280551lld:lifeskim
pubmed-article:8018093lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:8018093lifeskim:mentionsumls-concept:C0600688lld:lifeskim
pubmed-article:8018093lifeskim:mentionsumls-concept:C0450442lld:lifeskim
pubmed-article:8018093lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:8018093lifeskim:mentionsumls-concept:C0165264lld:lifeskim
pubmed-article:8018093pubmed:issue2Alld:pubmed
pubmed-article:8018093pubmed:dateCreated1994-7-27lld:pubmed
pubmed-article:8018093pubmed:abstractTextThe 13-week oral toxicity of nefiracetam (N-(2,6-dimethylphenyl)-2-(2-oxo- 1-pyrrolidinyl) acetamide, DM-9384, CAS 77191-36-7), a new cognition-enhancing agent, was investigated in Beagle dogs of both sexes. No change was observed in the 20 mg/kg group. Hypospermatogenesis and slightly increased deposition of hemosiderin in the spleen were seen in male dogs treated with 60 mg/kg or more. Dosing at 180 mg/kg induced a decrease in food consumption, increases in urinary volume and urinary protein, and renal papillary necrosis in both male and female dogs. The non-toxic dose was 20 mg/kg under these experimental conditions.lld:pubmed
pubmed-article:8018093pubmed:languageenglld:pubmed
pubmed-article:8018093pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8018093pubmed:citationSubsetIMlld:pubmed
pubmed-article:8018093pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8018093pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8018093pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8018093pubmed:statusMEDLINElld:pubmed
pubmed-article:8018093pubmed:monthFeblld:pubmed
pubmed-article:8018093pubmed:issn0004-4172lld:pubmed
pubmed-article:8018093pubmed:authorpubmed-author:KatoMMlld:pubmed
pubmed-article:8018093pubmed:authorpubmed-author:TakayamaSSlld:pubmed
pubmed-article:8018093pubmed:authorpubmed-author:SuzukiNNlld:pubmed
pubmed-article:8018093pubmed:authorpubmed-author:SugawaraTTlld:pubmed
pubmed-article:8018093pubmed:authorpubmed-author:AkahaneKKlld:pubmed
pubmed-article:8018093pubmed:issnTypePrintlld:pubmed
pubmed-article:8018093pubmed:volume44lld:pubmed
pubmed-article:8018093pubmed:ownerNLMlld:pubmed
pubmed-article:8018093pubmed:authorsCompleteYlld:pubmed
pubmed-article:8018093pubmed:pagination217-9lld:pubmed
pubmed-article:8018093pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:8018093pubmed:meshHeadingpubmed-meshheading:8018093-...lld:pubmed
pubmed-article:8018093pubmed:meshHeadingpubmed-meshheading:8018093-...lld:pubmed
pubmed-article:8018093pubmed:meshHeadingpubmed-meshheading:8018093-...lld:pubmed
pubmed-article:8018093pubmed:meshHeadingpubmed-meshheading:8018093-...lld:pubmed
pubmed-article:8018093pubmed:meshHeadingpubmed-meshheading:8018093-...lld:pubmed
pubmed-article:8018093pubmed:meshHeadingpubmed-meshheading:8018093-...lld:pubmed
pubmed-article:8018093pubmed:meshHeadingpubmed-meshheading:8018093-...lld:pubmed
pubmed-article:8018093pubmed:meshHeadingpubmed-meshheading:8018093-...lld:pubmed
pubmed-article:8018093pubmed:meshHeadingpubmed-meshheading:8018093-...lld:pubmed
pubmed-article:8018093pubmed:meshHeadingpubmed-meshheading:8018093-...lld:pubmed
pubmed-article:8018093pubmed:meshHeadingpubmed-meshheading:8018093-...lld:pubmed
pubmed-article:8018093pubmed:meshHeadingpubmed-meshheading:8018093-...lld:pubmed
pubmed-article:8018093pubmed:meshHeadingpubmed-meshheading:8018093-...lld:pubmed
pubmed-article:8018093pubmed:year1994lld:pubmed
pubmed-article:8018093pubmed:articleTitleThirteen-week oral toxicity study of the new cognition-enhancing agent nefiracetam in dogs.lld:pubmed
pubmed-article:8018093pubmed:affiliationDrug Safety Research Center, Developmental Research Laboratories, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.lld:pubmed
pubmed-article:8018093pubmed:publicationTypeJournal Articlelld:pubmed